Search research articles
Contact Us
Filters
Showing results (311-320 of 580) with videos related to
Page
of 58
Sort By:
Plos One
|
August 13, 2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel
Lucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, et al.
The Oncologist
|
May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Allison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
Grant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
The New England Journal of Medicine
|
September 8, 2010
Inhibition of mutated, activated BRAF in metastatic melanoma
Keith T Flaherty, Igor Puzanov, Kevin B Kim, et al.
British Journal of Cancer
|
August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
Karl D Lewis, James Larkin, Antoni Ribas, et al.
Nature
|
November 5, 2013
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
The Oncologist
|
May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Ryan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib
Melissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
April A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Page
of 58
Search research articles
Search
Showing results (311-320 of 580) with videos related to
Sort By:
Page
of 58
Plos One
|
August 13, 2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel
Lucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, et al.
The Oncologist
|
May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Allison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
Grant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
The New England Journal of Medicine
|
September 8, 2010
Inhibition of mutated, activated BRAF in metastatic melanoma
Keith T Flaherty, Igor Puzanov, Kevin B Kim, et al.
British Journal of Cancer
|
August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
Karl D Lewis, James Larkin, Antoni Ribas, et al.
Nature
|
November 5, 2013
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
The Oncologist
|
May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Ryan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib
Melissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
April A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Page
of 58